TrialJournal of the American Society of Nephrology : JASN2018

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.

Howard Trachtman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.